Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant meningococcal serogroup B vaccine + outer membrane vesicle
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal, Oral, Subcutaneous, Intraperitoneal, Intradermal
01
Overview
A combination vaccine formulated for *Neisseria meningitidis* serogroup B, consisting of recombinant surface protein antigens and purified outer membrane vesicles (OMVs) from targeted strains. OMVs are non-replicating nanostructures derived from Gram-negative bacterial membranes, primarily containing PorA (and sometimes additional outer membrane proteins like FetA or fHbp), which are potent immunogens. Recombinant proteins (such as fHbp, NadA, NHBA) are produced using recombinant DNA technology and added to broaden strain coverage. The vaccine acts by stimulating both humoral and cellular immunity, inducing strong bactericidal antibody responses against serogroup B meningococci through complement-mediated killing. OMVs contribute intrinsic adjuvant properties via pathogen-associated molecular patterns (PAMPs) that activate host Toll-like receptors, enhancing immune activation[1][5][7].
- Brand names
- BexseroMenBvacVA-MENGOC-BCMeNZB
- Other names
- meningococcal group B vaccine with outer membrane vesicleOMV-based MenB vaccine
02
Targets
TLR2 (Toll-like Receptor 2)NHBA (Neisseria heparin-binding antigen)PorB (Major outer membrane porin PorB)NadA (Neisseria adhesin A)FepA (Ferric enterobactin receptor FepA)OpcA (Outer membrane protein OpcA)TLR4 (Toll-like receptor 4)fHbp (Factor H binding protein)PorA (Major outer membrane protein PorA)
Beyond the preview
Go deeper on recombinant meningococcal serogroup B vaccine + outer membrane vesicle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant meningococcal serogroup B vaccine + outer membrane vesicle.